Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of GBT440 in Hepatic Impairment
NCT03114540Phase 1Completed
- Sponsor
- Pfizer
- Start
- Mar 2017
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of voxelotor in sickle cell disease (SCD) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Plasma Concentration at 28 days, Time to Maximum Plasma Concentration at 28 days and 2 more. Started Mar 2017; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT03114540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03114540.